29 April 2026
29 April 2026
Novartis’ Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future.
The pair will harness AI to discover and develop recombinases for precise, large-scale gene editing.
A PRV is issued by the FDA to sponsors whose products address certain rare paediatric diseases.
The collaboration leverages Fosun Pharma’s research and manufacturing strengths, as well as Arcera’s access to international markets.
With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.
The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
